Supernus Pharmaceuticals, Inc
Supernus Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing medicines for central nervous system diseases. Its portfolio includes approved and marketed therapies for ADHD, Parkinson’s disease-related movement disorders, epilepsy, migraine, postpartum depression, cervical dystonia, and chronic sialorrhea, along with a pipeline of CNS product candidates.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueApproved and marketed medicines for ADHD, Parkinson’s disease, epilepsy, migraine, dystonia, and sialorrhea.
Products distributed mainly through specialty pharmacies, including therapies for movement disorders and postpartum depression.
Revenue from partnered products such as ZURZUVAE under commercialization or profit-sharing arrangements.
Clinical-stage CNS candidates such as SPN-817, SPN-820, and SPN-443.
Products
Reported · share of revenue- Qelbree42.4 %
- GOCOVRI20.4 %
- Collaboration Revenue7.4 %
- APOKYN6.6 %
- Trokendi Xr5.9 %
- Other17.3 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Supernus sells primarily to pharmaceutical wholesalers, specialty pharmacies, and distributors, which then supply pharmacies, hospitals, and other healthcare customers. Some products are also purchased directly by physicians and hospitals, while certain therapies are distributed through specialty pharmacy channels because of patient support, access, and handling requirements.
Buy the majority of product sales for several brands and distribute into the broader pharmacy channel.
Buy and dispense therapies such as GOCOVRI, APOKYN, ONAPGO, and ZURZUVAE where patient support matters.
Handle product flow for brands sold through channel partners, especially in broad commercial access markets.
Purchase certain products directly, including MYOBLOC, for in-office or institutional use.
Indirectly consume products through downstream channels and influence access, rebates, and reimbursement.
Strategy
Supernus is focused on expanding its neuroscience franchise through commercial execution in ADHD and movement disorders while advancing a pipeline of CNS candidates. The company also uses business development and acquisitions to add marketed assets and broaden its portfolio, as shown by its Sage Therapeutics transaction and the addition of ZURZUVAE.
The company depends on branded product sales, so growth in core franchises supports scale and portfolio durability.
Clinical programs create future product opportunities and reduce reliance on older brands.
Acquisitions and collaborations can quickly expand the commercial portfolio and pipeline.
Patent expirations can erode legacy revenue, so portfolio renewal is important for continuity.
Geography
Supernus is headquartered in Rockville, Maryland and operates as a U.S.-based company with commercial activity centered in the United States. The business is exposed to U.S. reimbursement, FDA regulation, and domestic channel concentration, while some supply and vendor relationships extend outside the United States.
Risks
Supernus faces concentration in a few commercial products and channel partners, making revenue sensitive to prescription trends, reimbursement, and wholesaler purchasing patterns. The company also faces regulatory, patent, supply-chain, and acquisition-related risks that are common in specialty pharmaceuticals and can affect launches, margins, and asset values.
FDA requirements and payor coverage decisions can affect approval timing, pricing, and patient access.
Three wholesalers accounted for more than 15% each of product revenue, creating dependence on a few channel partners.
Loss of exclusivity on legacy products can sharply reduce revenue as generic competition enters.
The company relies on third-party manufacturers and suppliers, including non-U.S. vendors, for active ingredients and drug substances.
Exposure: API and clinical manufacturing supply
Business combinations require purchase accounting judgments and can create goodwill or intangible asset impairment exposure.
Accounting
Judgemental itemsProduct sales are recorded net of rebates, discounts, and estimated returns, so reserve estimates directly affect revenue.
Impact: Quarterly revenue and gross-to-net adjustments
Long lag times between sale and state Medicaid invoicing can require revisions to prior-period accruals.
Impact: Earnings volatility and reserve true-ups
The Sage acquisition requires fair value allocation across acquired assets, liabilities, goodwill, and contingent consideration.
Impact: Purchase accounting, amortization, and future impairment risk
Legacy products and acquired rights may need impairment testing if expected cash flows decline.
Impact: Non-cash charges to operating results
Similar listed companies
Publicly listed companies with a comparable business focus.
Praxis Precision Medicines, Inc.
PRAX · Pharmaceutical Preparations
Minerva Neurosciences, Inc.
NERV · Pharmaceutical Preparations
Axsome Therapeutics, Inc.
AXSM · Pharmaceutical Preparations
Axsome Therapeutics is a U.S.-based biopharmaceutical company focused on central nervous system (CNS) disorders, with a commercial portfolio built around AUVELITY, SUNOSI, and SYMBRAVO.
Vanda Pharmaceuticals Inc.
VNDA · Pharmaceutical Preparations
NeuroPace Inc
NPCE · Surgical & Medical Instruments & Apparatus
NeuroPace is a U.S.-based medical device company focused on epilepsy treatment through its implantable RNS System.
Neuronetics, Inc.
STIM · Surgical & Medical Instruments & Apparatus
Last updated: 24/09/2026